Pharmacogenetics and asthma: false hope or new dawn?

被引：17

作者：

Hall, I. P. ^{[1
]}

Sayers, I. ^{[1
]}

机构：

[1] Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham NG7 2UH, England

来源：

EUROPEAN RESPIRATORY JOURNAL | 2007年 / 29卷 / 06期

基金：

英国惠康基金;

关键词：

asthma genetics;

D O I：

10.1183/09031936.00088206

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pharmacogenetic approaches provide the opportunity to improve prescribing for asthmatic patients in order to optimise efficacy and prevent side-effects. Currently, there are comprehensive data available on the extent of genetic variation in the human genome that will further this area of research. However, less is known about the functional consequences of many of the identified polymorphisms in genes whose products may predict drug efficacy. In addition, there is a shortage of well-designed, adequately powered clinical studies in this area. This series summarises the current state of knowledge and identifies areas for further research.

引用

页码：1239 / 1245

页数：7

共 51 条

[1] Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT1 antagonist, pranlukast, in Japanese patients with moderate asthma [J].

Asano, K ;

Shiomi, T ;

Hasegawa, N ;

Nakamura, H ;

Kudo, H ;

Matsuzaki, T ;

Hakuno, H ;

Fukunaga, K ;

Suzuki, Y ;

Kanazawa, M ;

Yamaguchi, K .

PHARMACOGENETICS, 2002, 12 (07) :565-570

[2] β2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma [J].

Aziz, I ;

Hall, IP ;

McFarlane, LC ;

Lipworth, BJ .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (03) :337-341

[3] Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma [J].

Bleecker, Eugene R. ;

Yancey, Steven W. ;

Baitinger, Leslie A. ;

Edwards, Lisa D. ;

Klotsman, Michael ;

Anderson, Wayne H. ;

Dorinsky, Paul M. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (04) :809-816

[4] Blunted cardiac responses to receptor activation in subjects with Thr164Ile β2-adrenoceptors [J].

Brodde, OE ;

Büscher, R ;

Tellkamp, R ;

Radke, J ;

Dhein, S ;

Insel, PA .

CIRCULATION, 2001, 103 (08) :1048-1050

[5] Association analysis of β2 adrenoceptor polymorphisms with hypertension in a Black African population [J].

Candy, G ;

Samani, N ;

Norton, G ;

Woodiwiss, A ;

Radevski, I ;

Wheatley, A ;

Cockcroft, J ;

Hall, IP .

JOURNAL OF HYPERTENSION, 2000, 18 (02) :167-172

[6]

Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442

[7] Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy [J].

Donfack, J ;

Kogut, P ;

Forsythe, S ;

Solway, J ;

Ober, C .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (03) :527-532

[8] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].

Drazen, JM ;

Yandava, CN ;

Dubé, L ;

Szczerback, N ;

Hippensteel, R ;

Pillari, A ;

Israel, E ;

Schork, N ;

Silverman, ES ;

Katz, DA ;

Drajesk, J .

NATURE GENETICS, 1999, 22 (02) :168-170

[9] Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].

Drysdale, CM ;

McGraw, DW ;

Stack, CB ;

Stephens, JC ;

Judson, RS ;

Nandabalan, K ;

Arnold, K ;

Ruano, G ;

Liggett, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488

[10] Pharmacogenetics of asthma [J].

Fenech, A ;

Hall, IP .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (01) :3-15

← 1 2 3 4 5 6 →